News & Updates

Show Multimedia Only

Low-fructose diet may be beneficial in obesity, hypertension

05 Mar 2024

Sticking to a low-fructose diet helps improve several anthropometric and metabolic variables, which could have favourable effects on obesity and hypertension, according to a meta-analysis.

Low-fructose diet may be beneficial in obesity, hypertension

05 Mar 2024

Nirmatrelvir reduces the risk of long COVID

05 Mar 2024

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹

Nirmatrelvir reduces the risk of long COVID

05 Mar 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024 by

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024 by

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024

Existing interventions insufficient in easing physician burnout

04 Mar 2024

Several interventions for reducing physician burnout result in significant numerical improvements in some domains, but such improvements fall short of providing meaningful changes in clinical burnout, according to the results of a meta-analysis.

Existing interventions insufficient in easing physician burnout

04 Mar 2024

Depressed? Do some exercise, says study

04 Mar 2024 by

People who are suffering from depression may find relief by getting physically active, like walking or jogging, yoga, and strength training, a study suggests. More intense exercises also seem to provide greater benefits in reducing depression, while yoga and strength training are well tolerated versus other treatments.

Depressed? Do some exercise, says study

04 Mar 2024

Nonpreventable readmission prevalent in patients with cirrhosis

04 Mar 2024

Readmissions within 30 days are common among patients with cirrhosis, but most of these are not preventable, reveals a study.

Nonpreventable readmission prevalent in patients with cirrhosis

04 Mar 2024

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

04 Mar 2024

Receipt of the COVID-19 vaccine during the follicular phase of the menstrual cycle leads to changes in cycle length, as reported in a study.

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

04 Mar 2024

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

03 Mar 2024 by

Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

03 Mar 2024

News & Updates

Filter by Specialty:

Specialty:

Low-fructose diet may be beneficial in obesity, hypertension

Low-fructose diet may be beneficial in obesity, hypertension

Nirmatrelvir reduces the risk of long COVID

Nirmatrelvir reduces the risk of long COVID

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

High-dose PPI use among cirrhotic patients poses risk of death, complications

High-dose PPI use among cirrhotic patients poses risk of death, complications

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

Existing interventions insufficient in easing physician burnout

Existing interventions insufficient in easing physician burnout

Depressed? Do some exercise, says study

Depressed? Do some exercise, says study

Nonpreventable readmission prevalent in patients with cirrhosis

Nonpreventable readmission prevalent in patients with cirrhosis

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma